Searchable abstracts of presentations at key conferences in endocrinology

ea0008s7 | Zonation of the adrenal cortex�molecular signalling | SFE2004

Adrenomedullin in the adrenal

Hinson JP

Adrenomedullin is a vasoactive peptide which is classically produced by vascular endothelial cells. It has been identified in the rat adrenal gland where it has a zone-specific distribution, being produced by the zona glomerulosa and medulla, but not the inner zones (zona fasciculata and reticularis). There is also an extensive peptidergic innervation to the zona glomerulosa, but not to the other cortical zones.There are several possible reasons for this...

ea0011p310 | Diabetes, metabolism and cardiovascular | ECE2006

Adrenomedullin increases the expression of CLR and RAMP2 in microvascular endothelial cells

Schwarz N , Sidhu K , Kapas S , Hinson JP

Adrenomedullin (AM) is a multifunctional peptide hormone which plays a significant role in vasodilation and angiogenesis, implicating it in hypertension as well as in carcinogenesis. AM exerts its effects via the Calcitonin Receptor-Like Receptor (CLR) complexed with either Receptor Activity Modifying Protein (RAMP) 2 or 3.The aim of the present study is to investigate the biological actions, functions and possible target genes of AM in immortalized Huma...

ea0008p38 | Diabetes, metabolism and cardiovascular | SFE2004

CHARACTERISATION OF ADRENOMEDULLIN RECEPTOR (CRLR/RAMP2) EXPRESSION IN HUMAN MICROVASCULAR ENDOTHELIAL CELLS

Schwarz N , Sidhu K , Kapas S , Hinson JP

Adrenomedullin (ADM) is a multifunctional peptide which plays a significant role in vasodilation, angiogenisis and septic shock. It exerts its effects via the calcitonin receptor-like receptor (CRLR) in combination with either receptor associated protein (RAMP) 2 or 3. However the regulation of the ADM receptors is still widely unknown (1). In the present study the effects of adrenomedullin on immortalized Human Microvascular Endothelial Cells (HMECs) was investigated. Endothe...

ea0011p625 | Neuroendocrinology and behaviour | ECE2006

Dehydroepiandrosterone (DHEA) improves psychological well-being in male and female hypopituitary patients in addition to growth hormone replacement (GHR)

Brooke AM , Kalingag LA , Miraki-Moud F , Camacho-Hubner C , Maher KT , Walker DM , Hinson JP , Monson JP

Hypopituitarism is associated with profound androgen deficiency, even in patients who are adrenocorticotrophic hormone (ACTH) replete. DHEA has been shown to have a beneficial effect on well-being in patients with adrenal failure. We hypothesised that DHEA may be additive to the known effects of GH on psychological well-being in patients with hypopituitarism. In a double blind placebo controlled trial 50 mg DHEA or placebo was added to standard replacement, including growth ho...